FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169023839> ?p ?o ?g. }

• W3169023839 abstract "Monoclonal antibodies (mAbs) are novel, effective therapeutics for the treatment of inadequately controlled severe asthma. Knowledge of the anaphylaxis risks related to different mAbs is essential for their appropriate and safe administration. This study aimed to evaluate the associations between different mAbs and anaphylactic reactions by applying statistical approaches to pharmacovigilance data.This was a retrospective study using data from the US Food and Drug Administration Adverse Event Reporting System database from January 2004 to September 2020. A total of 2006 reports of anaphylaxis related to benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab were obtained through data mining. The clinical characteristics of the cases were analyzed, and the risk signals of anaphylactic reactions and corresponding outcomes were investigated in the five mAbs.The patients were mainly young and middle-aged adults, with markedly more women than men. Omalizumab, benralizumab, reslizumab, and mepolizumab showed positive signals for anaphylaxis, while only dupilumab showed a negative signal. The risk of initial or prolonged hospitalization due to anaphylaxis was significantly higher in the benralizumab group than in the omalizumab group (42.86% vs. 28.92%, p = 0.024). Further, when anaphylaxis to omalizumab occurred, patients with asthma were more likely to have life-threatening outcomes than those with chronic urticaria (18.0% vs. 12.9%, p = 0.022).In the current real-world study, the positive anaphylaxis signals related to omalizumab, benralizumab, reslizumab, and mepolizumab suggested the need for the close monitoring of patients after drug use, and dupilumab showed a negative signal for anaphylaxis." @default.
• W3169023839 created "2021-06-22" @default.
• W3169023839 creator A5010185627 @default.
• W3169023839 creator A5010710133 @default.
• W3169023839 creator A5014667245 @default.
• W3169023839 creator A5017120573 @default.
• W3169023839 creator A5066294981 @default.
• W3169023839 creator A5078900483 @default.
• W3169023839 date "2021-06-01" @default.
• W3169023839 modified "2023-10-06" @default.
• W3169023839 title "Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab" @default.
• W3169023839 cites W1967555951 @default.
• W3169023839 cites W1981809734 @default.
• W3169023839 cites W1988100739 @default.
• W3169023839 cites W2004147651 @default.
• W3169023839 cites W2009216796 @default.
• W3169023839 cites W2035855298 @default.
• W3169023839 cites W2049317464 @default.
• W3169023839 cites W2064716383 @default.
• W3169023839 cites W2097022788 @default.
• W3169023839 cites W2147598330 @default.
• W3169023839 cites W2152815119 @default.
• W3169023839 cites W2171821819 @default.
• W3169023839 cites W2581167339 @default.
• W3169023839 cites W2742975673 @default.
• W3169023839 cites W2791685657 @default.
• W3169023839 cites W2791869517 @default.
• W3169023839 cites W2894926072 @default.
• W3169023839 cites W2968720572 @default.
• W3169023839 cites W2988410006 @default.
• W3169023839 cites W3000900852 @default.
• W3169023839 cites W3003535484 @default.
• W3169023839 cites W3034358203 @default.
• W3169023839 cites W3088121765 @default.
• W3169023839 cites W3109451132 @default.
• W3169023839 cites W3118304729 @default.
• W3169023839 cites W92486268 @default.
• W3169023839 doi "https://doi.org/10.1002/clt2.12038" @default.
• W3169023839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8175040" @default.
• W3169023839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34123366" @default.
• W3169023839 hasPublicationYear "2021" @default.
• W3169023839 type Work @default.
• W3169023839 sameAs 3169023839 @default.
• W3169023839 citedByCount "18" @default.
• W3169023839 countsByYear W31690238392021 @default.
• W3169023839 countsByYear W31690238392022 @default.
• W3169023839 countsByYear W31690238392023 @default.
• W3169023839 crossrefType "journal-article" @default.
• W3169023839 hasAuthorship W3169023839A5010185627 @default.
• W3169023839 hasAuthorship W3169023839A5010710133 @default.
• W3169023839 hasAuthorship W3169023839A5014667245 @default.
• W3169023839 hasAuthorship W3169023839A5017120573 @default.
• W3169023839 hasAuthorship W3169023839A5066294981 @default.
• W3169023839 hasAuthorship W3169023839A5078900483 @default.
• W3169023839 hasBestOaLocation W31690238391 @default.
• W3169023839 hasConcept C126322002 @default.
• W3169023839 hasConcept C141105273 @default.
• W3169023839 hasConcept C159654299 @default.
• W3169023839 hasConcept C16005928 @default.
• W3169023839 hasConcept C197934379 @default.
• W3169023839 hasConcept C203014093 @default.
• W3169023839 hasConcept C207480886 @default.
• W3169023839 hasConcept C2775933838 @default.
• W3169023839 hasConcept C2776042228 @default.
• W3169023839 hasConcept C2777037409 @default.
• W3169023839 hasConcept C2777832160 @default.
• W3169023839 hasConcept C2778564945 @default.
• W3169023839 hasConcept C2779185760 @default.
• W3169023839 hasConcept C2779824493 @default.
• W3169023839 hasConcept C71924100 @default.
• W3169023839 hasConceptScore W3169023839C126322002 @default.
• W3169023839 hasConceptScore W3169023839C141105273 @default.
• W3169023839 hasConceptScore W3169023839C159654299 @default.
• W3169023839 hasConceptScore W3169023839C16005928 @default.
• W3169023839 hasConceptScore W3169023839C197934379 @default.
• W3169023839 hasConceptScore W3169023839C203014093 @default.
• W3169023839 hasConceptScore W3169023839C207480886 @default.
• W3169023839 hasConceptScore W3169023839C2775933838 @default.
• W3169023839 hasConceptScore W3169023839C2776042228 @default.
• W3169023839 hasConceptScore W3169023839C2777037409 @default.
• W3169023839 hasConceptScore W3169023839C2777832160 @default.
• W3169023839 hasConceptScore W3169023839C2778564945 @default.
• W3169023839 hasConceptScore W3169023839C2779185760 @default.
• W3169023839 hasConceptScore W3169023839C2779824493 @default.
• W3169023839 hasConceptScore W3169023839C71924100 @default.
• W3169023839 hasFunder F4320321001 @default.
• W3169023839 hasIssue "4" @default.
• W3169023839 hasLocation W31690238391 @default.
• W3169023839 hasLocation W31690238392 @default.
• W3169023839 hasLocation W31690238393 @default.
• W3169023839 hasLocation W31690238394 @default.
• W3169023839 hasOpenAccess W3169023839 @default.
• W3169023839 hasPrimaryLocation W31690238391 @default.
• W3169023839 hasRelatedWork W2991717185 @default.
• W3169023839 hasRelatedWork W3003535484 @default.
• W3169023839 hasRelatedWork W3022770807 @default.
• W3169023839 hasRelatedWork W3034358203 @default.
• W3169023839 hasRelatedWork W3119831431 @default.
• W3169023839 hasRelatedWork W3169023839 @default.
• W3169023839 hasRelatedWork W3199319179 @default.

• next